Singer Colbie Caillat partners with Raw Beauty Talks
VANCOUVER, B.C. — Grammy-winning singer Colbie Caillat has teamed up with Raw Beauty Talks, an organization dedicated to facilitating a shift from beauty imprisonment to beauty empowerment, in her new music video "Try," which Caillat describes "an anthem for women to accept who they are and be comfortable showing it.”
The video features pictures of celebrities like Sheryl Crow, Miranda Lambert, and Sara Bareilles alongside everyday women, all wearing little to no make up.
Erin Treloar founded Raw Beauty Talks in hopes of starting a conversation around the challenges women face in accepting themselves in a society that promotes Photoshop, plastic surgery and images of unattainable beauty standards. Well aware of the dangerous affect superficial beauty standards have on young women, Treloar struggled with an eating disorder in her teens. Her hope with Raw Beauty Talks is that the next generation will embrace a more realistic standard of beauty.
"What if small lashes, wrinkled skin, sun spots and laugh lines became the mark of beauty? What if we were happier with our physical appearance? Would that translate into our overall happiness?" asked Treloar. "I don’t know the answer to these questions, but the voice inside me is telling me we need to find out."
Moody’s: New cancer drugs represent significant growth opportunity
NEW YORK — New approaches to treating cancer are creating big growth opportunities for the pharmaceutical industry, Moody’s Investors Service stated in a report released Thursday titled "Cancer Breakthroughs Bring New Options for Patients and Revenue Streams to Big Pharma." Drugs for the treatment of solid tumors in prevalent cancer types will serve a large and growing market, the report noted.
"The high incidence of new cancer cases each year, increased life expectancy for patients and a expanding number of treatment options will drive strong growth in the market for solid tumor treatments at least though 2020," stated Michael Levesque, SVP Moody’s. "Several drugs for the treatment of tumors in melanoma and lung and breast cancer are pending near-term approvals, while others could be launched in the next few years."
The new drugs fall into three main categories, Levesque noted. PD-1/PD-L1 inhibitors represent the greatest potential in treating a wide range of solid tumors. They fall into a broader category known as immunotherapy, which differs from most current treatments by targeting the tumor itself. Merck and Bristol-Myers Squibb are best positioned in the race to launch new immunotherapy drugs, with Merck possibly doing so later this year. And while Roche and AstraZeneca are slightly behind, they still stand to benefit from this high-growth area.
A second category known as CDK 4/6 inhibitors encompasses several experimental drugs that could meet an unmet need in treating breast cancer, according to the report. Breast cancer is one of the most frequently diagnosed types of cancer, and will account for 16% of new cases of solid tumors this year. Pfizer will be the first to file in the class with its drug palbociclib, and is poised to be the leader. Novartis and Eli Lilly are also testing products in late-stage clinical trials.
AbbVie and AstraZeneca both have large opportunities in a new class of cancer drugs known as PARP inhibitors. When used after chemotherapy, PARP inhibitors prevent a protein in tumor cells from repairing the tumor. AbbVie’s PARP inhibitor is in phase III for a select type of breast cancer and in non-small cell lung cancer, while AstraZeneca has filed its PARP inhibitor for use in the treatment of ovarian cancer.
Beyond these categories, several other cancer drugs in the pipeline represent medium to large opportunities, according to the report. Lilly has received approval for its drug Cyramza, for the treatment of gastric cancer. Additionally, both Roche and Novartis have deep oncology pipelines with a mix of approved drugs in new indications and new chemical entities that will drive incremental growth over the next several years.
Survey: Less impulsive online shoppers result in smaller market baskets
LONDON — According to a consumer survey from eDigitalResearch released Friday, online grocery shoppers tend to buy fewer impulse purchases online than in store, resulting in smaller basket sizes.
The survey of 1,154 online grocery shoppers found that 29% of respondents feel that they make far fewer impulse purchases online than in store. In comparison, just 7% said that they purchase more additional impulse buys online than they do in a store, highlighting a significant potential threat for retailers and their bottom lines, especially as more and more consumers switch to online shopping.
"The growth of online has the ability to drastically hamper supermarkets, retailers and suppliers," stated Derek Eccleston, commercial director at eDigitalResearch. "With more of us becoming all the more reliant on online and digital technologies, the online grocery market is only likely to grow. These results suggest that with this online growth, supermarkets are going to see overall spend shrink," he said. "They therefore need to be working closely with suppliers to understand this new breed of grocery shopper — they need to know how they shop and why, as well as what makes them buy what they do — in an effort to encourage online shoppers to spend more."
However, the results also suggest that online shoppers are more likely to switch among various brands compared to their in-store counterparts. Of those online grocery shoppers surveyed, just 10% said that they always stick to the same brands for particular items, suggesting that there is a huge opportunity to influence people’s purchase decisions and disrupt their journeys online.
Price is one of the key drivers behind brand switches, suggesting that promotions and offers are perhaps the best way to disrupt online grocery shops and encourage impulse buys. However, loyalty card promotions, search positions and product images all also have an effect on how people shop online.
"These results prove that, when it comes to buying food and drink, by understanding changing online consumer behaviours and what makes online grocery shoppers tick, suppliers and supermarkets will be able to better influence online purchase decisions, increase spend an minimise the threat that the growth of online grocery shopping poses," Eccleston said.
The results come from eDigitalResearch’s recent study into the current state of online grocery shopping to help supermarkets and suppliers better understand this growing breed of consumer, the full results of which will be available later in June.